Skip to main content
. Author manuscript; available in PMC: 2019 Jul 2.
Published in final edited form as: Mol Pharm. 2018 May 30;15(7):2606–2613. doi: 10.1021/acs.molpharmaceut.8b00133

Figure 1.

Figure 1

PET imaging of 86Y-DTPA-TRC105. (A) Serial representative PET MIP images reveal prominent uptake in the 4T1 tumor, indicated by a red arrow. (B) ROI analysis of blood pool and tumor uptake. (C) Ex vivo biodistribution of 86Y-DTPA-TRC105 at 48 h postinjection, n = 4.